C4X Discovery Holdings plc has out-licensed a its preclinical NRF2 activator programme for inflammatory and respiratory diseases to AstraZeneca PLC in a deal that could be worth up to $402m as part of an underlying diversification strategy.
C4XD Inks Third Major Deal, This Time With AZ For Oral COPD Drug
Gets $2m Upfront
The UK firm has out-licensed its NRF2 activator programme to AstraZeneca in its third major deal of the year as it works to stabilize cash flow through a broad-ranging approach to partnerships.
More from Deals
More from Business
• By
The German firm’s chairman, Hubertus von Baumbach, is adopting a ‘wait-and-see’ approach to the threat of pharma tariffs.
• By
Trump announced a 26% reciprocal tariff on India but a country-agnostic exemption of pharmaceuticals implies that the interests of Indian firms and the US consumer are protected for now. What is Indian pharma’s business exposure and what is domestic industry saying?
• By
Industry lobbied for pharmaceuticals to be exempt from Trump’s sweeping US tariffs and the effort appears to have paid off. J&J, Lilly and Merck & Co. even got shout outs.